Melanoma

New Indication: Perioperative Pembrolizumab in Melanoma

2023-04-14

  • Study

    Open-label, phase 2 study
    Treatment naïve resectable sage IIIB-IVC metastatic melanoma (cutaneous, acral, or mucosal)
    Pembrolizumab: Neoadjuvant-adjuvant (n=154) vs. Adjuvant (n=159)


  • Efficacy

    2-year EFS: 72% vs.49%, p=0.004

  • Safety

    Grade 3 AEs: ALT increased (1% vs. NA), AST increased (1% vs. NA)


    • N Engl J Med 2023; 388:813-823

    Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

    http://doi.org/10.1056/NEJMoa2211437

    Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023